Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved Yeztugo ®— the company’ s injectable HIV-1 capsid inhibitor— as pre-exposure prophylaxis to ...

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The ...